Verve Therapeutics (NASDAQ: VERV)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.620 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Verve Therapeutics (NASDAQ: VERV) through any online brokerage.
Other companies in Verve Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), Replimune Group (NASDAQ:REPL), Kiniksa Pharmaceuticals (NASDAQ:KNSA), PMV Pharma (NASDAQ:PMVP) and CTI BioPharma (NASDAQ:CTIC).
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by BMO Capital on Friday, June 17, 2022. The analyst firm set a price target for 48.00 expecting VERV to rise to within 12 months (a possible 207.10% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Verve Therapeutics (NASDAQ: VERV) is $15.63 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Verve Therapeutics.
Verve Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Verve Therapeutics.
Verve Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.